MorphoSys AG (XSWX:MOR) EPS (Diluted) : CHF0.00 (TTM As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG EPS (Diluted)?

MorphoSys AG's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was CHF0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.00.

MorphoSys AG's EPS (Basic) for the three months ended in Dec. 2023 was CHF0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.00.

MorphoSys AG's EPS without NRI for the three months ended in Dec. 2023 was CHF0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, MorphoSys AG's highest 3-Year average EPS without NRI Growth Rate was 214.70% per year. The lowest was -158.20% per year. And the median was -9.10% per year.

MorphoSys AG EPS (Diluted) Historical Data

The historical data trend for MorphoSys AG's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG EPS (Diluted) Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-3.56

3.21

-16.03

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of MorphoSys AG's EPS (Diluted)

For the Biotechnology subindustry, MorphoSys AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's PE Ratio falls into.

MorphoSys AG EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

MorphoSys AG's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-178.933	-	0)	/	34.1488
	=	-5.24

MorphoSys AG's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(45.518	-	0)	/	34.1607
	=	1.33

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0.00

MorphoSys AG (XSWX:MOR) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

MorphoSys AG EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (XSWX:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.